tiprankstipranks
Advertisement
Advertisement

NMRA Stock Latest News

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
The FlyClear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
3h ago
LBRX
NMRA
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
PremiumThe Fly
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
3h ago
LBRX
NMRA
Neumora Ends Navacaprant After Phase 3 Trial Failure
PremiumCompany Announcements
Neumora Ends Navacaprant After Phase 3 Trial Failure
13h ago
8K
NMRA
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
PremiumThe Fly
Neumora Therapeutics announces KOASTAL studies miss primary endpoint
13h ago
NMRA
Neumora Shareholders Approve Directors, Auditor and Executive Pay
PremiumCompany Announcements
Neumora Shareholders Approve Directors, Auditor and Executive Pay
17d ago
8K
NMRA
Analyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts
PremiumRatingsAnalyst Reiterates Buy on Neumora, Maintaining $18 Price Target Ahead of Key KOASTAL-2/3 Depression Readouts
20d ago
NMRA
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst
Premium
Company Announcements
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst
24d ago
NMRA
Neumora Therapeutics Securities Lawsuit Enters New Procedural Phase as Plaintiffs Prepare New Complaint
Premium
Class Action
Neumora Therapeutics Securities Lawsuit Enters New Procedural Phase as Plaintiffs Prepare New Complaint
28d ago
NMRA
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
PremiumRatings
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target
1M ago
NMRA
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
PremiumRatings
Analyst Initiates Buy on Neumora, Citing Compelling Risk/Reward Ahead of Key Navacaprant Readouts and Broader Pipeline Upside
1M ago
NMRA
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
PremiumThe Fly
Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)
1M ago
NMRA
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
PremiumRatings
Neumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy Rating
2M ago
NMRA
Neumora Therapeutics management to meet with Piper Sandler
PremiumThe FlyNeumora Therapeutics management to meet with Piper Sandler
2M ago
NMRA
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
Premium
Company Announcements
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead
3M ago
NMRA
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
Premium
Company Announcements
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access
3M ago
NMRA
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
PremiumThe Fly
Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
3M ago
IQ
SR
Options Volatility and Implied Earnings Moves Today, March 30, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 30, 2026
3M ago
CBAT
DFDV
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
PremiumThe Fly
Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)
3M ago
NMRA
NMRA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
NMRA Earnings this Week: How Will it Perform?
3M ago
NMRA
Neumora Therapeutics management to meet virtually with Needham
PremiumThe FlyNeumora Therapeutics management to meet virtually with Needham
4M ago
NMRA
Neumora upgraded to Outperform from Market Perform at William Blair
Premium
The Fly
Neumora upgraded to Outperform from Market Perform at William Blair
4M ago
NMRA
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
Premium
Ratings
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora
4M ago
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >